142 related articles for article (PubMed ID: 31434110)
1. USPSTF Recommendations for BRCA1 and BRCA2 Testing in the Context of a Transformative National Cancer Control Plan.
Rajagopal PS; Nielsen S; Olopade OI
JAMA Netw Open; 2019 Aug; 2(8):e1910142. PubMed ID: 31434110
[No Abstract] [Full Text] [Related]
2. USPSTF recommends BRCA testing in women based on familial history.
Dangi-Garimella S
Am J Manag Care; 2014 Mar; 20(5 Spec No.):E6. PubMed ID: 25618620
[No Abstract] [Full Text] [Related]
3. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.
; Owens DK; Davidson KW; Krist AH; Barry MJ; Cabana M; Caughey AB; Doubeni CA; Epling JW; Kubik M; Landefeld CS; Mangione CM; Pbert L; Silverstein M; Simon MA; Tseng CW; Wong JB
JAMA; 2019 Aug; 322(7):652-665. PubMed ID: 31429903
[TBL] [Abstract][Full Text] [Related]
4. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
Nelson HD; Pappas M; Cantor A; Haney E; Holmes R
JAMA; 2019 Aug; 322(7):666-685. PubMed ID: 31429902
[TBL] [Abstract][Full Text] [Related]
5. Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation.
Finch AP; Lubinski J; Møller P; Singer CF; Karlan B; Senter L; Rosen B; Maehle L; Ghadirian P; Cybulski C; Huzarski T; Eisen A; Foulkes WD; Kim-Sing C; Ainsworth P; Tung N; Lynch HT; Neuhausen S; Metcalfe KA; Thompson I; Murphy J; Sun P; Narod SA
J Clin Oncol; 2014 May; 32(15):1547-53. PubMed ID: 24567435
[TBL] [Abstract][Full Text] [Related]
6. Summaries for patients. Assessing the genetic risk for BRCA-related breast or ovarian cancer in women: recommendations from the U.S. Preventive Services Task Force.
Ann Intern Med; 2014 Feb; 160(4):I-16. PubMed ID: 25006622
[No Abstract] [Full Text] [Related]
7. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. Preventive Services Task Force recommendation statement.
Moyer VA;
Ann Intern Med; 2014 Feb; 160(4):271-81. PubMed ID: 24366376
[TBL] [Abstract][Full Text] [Related]
8. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation.
Finch A; Beiner M; Lubinski J; Lynch HT; Moller P; Rosen B; Murphy J; Ghadirian P; Friedman E; Foulkes WD; Kim-Sing C; Wagner T; Tung N; Couch F; Stoppa-Lyonnet D; Ainsworth P; Daly M; Pasini B; Gershoni-Baruch R; Eng C; Olopade OI; McLennan J; Karlan B; Weitzel J; Sun P; Narod SA;
JAMA; 2006 Jul; 296(2):185-92. PubMed ID: 16835424
[TBL] [Abstract][Full Text] [Related]
9. Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers.
Domchek SM; Friebel TM; Garber JE; Isaacs C; Matloff E; Eeles R; Evans DG; Rubinstein W; Singer CF; Rubin S; Lynch HT; Daly MB; Weitzel J; Ganz PA; Pichert G; Olopade OI; Tomlinson G; Tung N; Blum JL; Couch F; Rebbeck TR
Breast Cancer Res Treat; 2010 Nov; 124(1):195-203. PubMed ID: 20180014
[TBL] [Abstract][Full Text] [Related]
10. Timing of referral for genetic counseling and genetic testing in patients with ovarian, fallopian tube, or primary peritoneal carcinoma.
Novetsky AP; Smith K; Babb SA; Jeffe DB; Hagemann AR; Thaker PH; Powell MA; Mutch DG; Massad LS; Zighelboim I
Int J Gynecol Cancer; 2013 Jul; 23(6):1016-21. PubMed ID: 23748176
[TBL] [Abstract][Full Text] [Related]
11. Genetic testing for hereditary breast and ovarian cancer and the USPSTF recommendations.
Wood ME; Garber JE; Isaacs C; Masood S; Bedrosian I; Tung N; Chun J; Schnabel FR; Arun BK;
Breast J; 2019 Jul; 25(4):575-577. PubMed ID: 31280501
[No Abstract] [Full Text] [Related]
12. Quantitative analysis of γ-H2AX and p53 nuclear expression levels in ovarian and fallopian tube epithelium from risk-reducing salpingo-oophorectomies in BRCA1 and BRCA2 mutation carriers.
Staff S; Tolonen T; Laasanen SL; Mecklin JP; Isola J; Mäenpää J
Int J Gynecol Pathol; 2014 May; 33(3):309-16. PubMed ID: 24681744
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up.
Olivier RI; van Beurden M; Lubsen MA; Rookus MA; Mooij TM; van de Vijver MJ; van't Veer LJ
Br J Cancer; 2004 Apr; 90(8):1492-7. PubMed ID: 15083174
[TBL] [Abstract][Full Text] [Related]
14. Does the diagnosis of breast or ovarian cancer trigger referral to genetic counseling?
Powell CB; Littell R; Hoodfar E; Sinclair F; Pressman A
Int J Gynecol Cancer; 2013 Mar; 23(3):431-6. PubMed ID: 23354368
[TBL] [Abstract][Full Text] [Related]
15. Proposal on Raloxifene use after prophylactic salpingo-oophorectomy in BRCA1-2: hypothesis and rationale.
Gizzo S; Noventa M; Saccardi C; Litta P; D'Antona D; Nardelli GB
Eur J Cancer Prev; 2014 Nov; 23(6):514-5. PubMed ID: 25254310
[No Abstract] [Full Text] [Related]
16. Precision medicine meets public health: population screening for BRCA1 and BRCA2.
Levy-Lahad E; Lahad A; King MC
J Natl Cancer Inst; 2015 Jan; 107(1):420. PubMed ID: 25550384
[No Abstract] [Full Text] [Related]
17. Prophylactic salpingo-oophorectomy in a series of 89 women carrying a BRCA1 or a BRCA2 mutation.
Laki F; Kirova YM; This P; Plancher C; Asselain B; Sastre X; Stoppa-Lyonnet D; Salmon R;
Cancer; 2007 May; 109(9):1784-90. PubMed ID: 17351952
[TBL] [Abstract][Full Text] [Related]
18. Genetic/familial high-risk assessment: breast and ovarian.
Daly MB; Axilbund JE; Buys S; Crawford B; Farrell CD; Friedman S; Garber JE; Goorha S; Gruber SB; Hampel H; Kaklamani V; Kohlmann W; Kurian A; Litton J; Marcom PK; Nussbaum R; Offit K; Pal T; Pasche B; Pilarski R; Reiser G; Shannon KM; Smith JR; Swisher E; Weitzel JN;
J Natl Compr Canc Netw; 2010 May; 8(5):562-94. PubMed ID: 20495085
[No Abstract] [Full Text] [Related]
19. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: a systematic review to update the U.S. Preventive Services Task Force recommendation.
Nelson HD; Pappas M; Zakher B; Mitchell JP; Okinaka-Hu L; Fu R
Ann Intern Med; 2014 Feb; 160(4):255-66. PubMed ID: 24366442
[TBL] [Abstract][Full Text] [Related]
20. Management updates for women with a BRCA1 or BRCA2 mutation.
Nusbaum R; Isaacs C
Mol Diagn Ther; 2007; 11(3):133-44. PubMed ID: 17570734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]